Search results for "OTHER"

showing 10 items of 12132 documents

More about genetically modified tumour vaccines

1998

medicine.medical_treatmentGenetic enhancementGene Transfer TechniquesMEDLINEImmunotherapy ActiveGenetic TherapyImmunotherapyBiologyCancer VaccinesGenetically modified organismGeneticsmedicineCancer researchCytokinesHumansMolecular MedicineMolecular BiologyGene Therapy
researchProduct

Dendritic Cell-Specific Biolistic Transfection Using the Fascin Gene Promoter

2012

The transcriptional targeting of gene expression to selected cells by cell type-specific promoters displays a fundamental tool in gene therapy. In immunotherapy, dendritic cells (DCs) are pivotal for the elicitation of antigen-specific immune responses following gene gun-mediated biolistic transfection. Here we report on transcriptional targeting of murine skin DCs using plasmids which include the promoter of the gene of the cytoskeletal protein fascin to control antigen production. Fascin, which is mandatory for the formation of dendrites, is synthesized among the hematopoietic cells exclusively by activated DCs. The activity of the promoter of the fascin gene reflects the endogenous produ…

medicine.medical_treatmentGenetic enhancementchemical and pharmacologic phenomenaPromoterImmunotherapyDendritic cellTransfectionBiologyGene expressionmedicinebiology.proteinCancer researchGeneFascin
researchProduct

Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

2021

Abstract The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogen…

medicine.medical_treatmentIFNBortezomibMiceImmune systemimmune system diseaseshemic and lymphatic diseasesimmunogenic cell deathmedicineAnimalsHumansbortezomib myelomaMultiple myelomaBortezomibbusiness.industryImmunityMembrane ProteinsGeneral MedicineImmunotherapymedicine.diseaseNucleotidyltransferasesStingApoptosisCancer researchProteasome inhibitorImmunogenic cell deathMultiple MyelomabusinessSignal TransductionSTINGmedicine.drugBlood Cancer Discovery
researchProduct

Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions.

1998

Culture conditions for human dendritic cells (DC) have been developed by several laboratories. Most of these culture methods, however, have used conditions involving fetal calf serum (FCS) to generate DC in the presence of granulocyte-macrophage colony-stimulating factor and interleukin (IL)-4. Recently, alternative culture conditions have been described using an additional stimulation with monocyte-conditioned medium (MCM) and FCS-free media to generate DC. As MCM is a rather undefined cocktail, the yield and quality of DC generated by these cultures varies substantially. We report that a defined cocktail of tumor necrosis factor (TNF)-alpha, IL-1beta and IL-6 equals MCM in its potency to …

medicine.medical_treatmentImmunologyBiologyCulture Media Serum-FreeProinflammatory cytokineFlow cytometryImmunophenotypingInterferonCell MovementmedicineImmunology and AllergyHumansCells Culturedmedicine.diagnostic_testInterleukinCell DifferentiationImmunotherapyDendritic CellsFlow CytometryMolecular biologyCytokineImmunologyProstaglandinsCytokinesTumor necrosis factor alphaCD8medicine.drugEuropean journal of immunology
researchProduct

Efficient Killing of Human Colon Cancer Stem Cells by γδ T Lymphocytes

2009

Abstract Colon cancer comprises a small population of cancer stem cells (CSC) that is responsible for tumor maintenance and resistant to cancer therapies, possibly allowing for tumor recapitulation once treatment stops. We previously demonstrated that such chemoresistance is mediated by autocrine production of IL-4 through the up-regulation of antiapoptotic proteins. Several innate and adaptive immune effector cells allow for the recognition and destruction of cancer precursors before they constitute the tumor mass. However, cellular immune-based therapies have not been experimented yet in the population of CSCs. Here, we show that the bisphosphonate zoledronate sensitizes colon CSCs to Vγ9…

medicine.medical_treatmentImmunologyImmunotherapyBiologyNKG2DCell biologyImmune systemGranzymeCancer stem cellmedicinebiology.proteinImmunology and AllergyCytotoxic T cellStem cellAutocrine signallingThe Journal of Immunology
researchProduct

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

2001

We identified a tumor-associated cytotoxic T lymphocyte (CTL) epitope derived from the widely expressed human MDM2 oncoprotein and were able to bypass self-tolerance to this tumor antigen in HLA-A*0201 (A2.1) transgenic mice and by generating A2.1-negative, allo-A2.1-restricted human T lymphocytes. A broad range of malignant, as opposed to nontransformed cells, were killed by high-avidity transgenic mouse and allogeneic human CTLs specific for the A2.1-presented MDM2 epitope. Whereas the self-A2.1-restricted human T cell repertoire gave rise only to low-avidity CTLs unable to recognize the natural MDM2 peptide, human A2.1+ T lymphocytes were turned into efficient MDM2-specific CTLs upon exp…

medicine.medical_treatmentImmunologyT-cell receptorchemical and pharmacologic phenomenaImmunotherapyBiologyMajor histocompatibility complexMolecular biologyTumor antigenEpitopeCTL*Antigenmedicinebiology.proteinImmunology and AllergyCytotoxic T cell
researchProduct

An unconventional TRAIL to cancer therapy

2013

Cellular immunotherapy offers novel, safe, and effective routes to treating cancer. However, approaches utilizing cytotoxic CD8+ T cells are hampered by the need to identify suitable target antigens that are expressed by tumor cells but not healthy tissues, and that are recognized with sufficient affinity. Most importantly, the applicability of CD8+ T-cell-based therapies is governed by the MHC restriction of tumor-specific epitopes, thereby limiting the potential benefit to patients carrying the appropriate MHC haplotype. Alternative approaches to harness the immune system against tumors exploit non-MHC-restricted γδ T cells that recognize stress-induced changes in transformed cells. A new…

medicine.medical_treatmentImmunologychemical and pharmacologic phenomenaImmunotherapyMHC restrictionBiologyNKG2DMajor histocompatibility complexEpitopeImmune systemAntigenImmunologymedicinebiology.proteinImmunology and AllergyCytotoxic T cellEuropean Journal of Immunology
researchProduct

Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.

2005

Type I interferons are associated with lupus. Genes that are regulated by IFN-alpha are upregulated in pediatric lupus patients. Gene deletion of the IFN-alpha/beta receptor in experimental lupus-like NZB mice results in reduced disease activity. Conversely, IFN-beta is a well-established treatment in multiple sclerosis, another autoimmune disease. For determining whether IFN-beta treatment is harmful or beneficial in lupus, MRL-Fas(lpr) mice were injected with this type I IFN. Treatment was initiated in MRL-Fas(lpr) mice with mild and advanced disease. IFN-beta was highly effective in prolonging survival and ameliorating the clinical (renal function, proteinuria, splenomegaly, and skin les…

medicine.medical_treatmentLupus nephritisImmunoglobulinsurologic and male genital diseasesmedicine.disease_causeKidneyAutoimmunityMiceImmune systemimmune system diseasesmedicineAnimalsLupus Erythematosus SystemicUreaskin and connective tissue diseasesSkinAutoimmune diseaseLupus erythematosusSystemic lupus erythematosusbusiness.industryGeneral MedicineImmunotherapymedicine.diseaseFlow CytometryLupus NephritisMice Mutant StrainsRecombinant ProteinsDisease Models AnimalProteinuriaCytokineNephrologyImmunoglobulin GImmunologyInterferon Type IDisease ProgressionbusinessCell DivisionJournal of the American Society of Nephrology : JASN
researchProduct

A hyaluronic acid/cyclodextrin based injectable hydrogel for local doxorubicin delivery to solid tumors

2020

Localized delivery of anticancer drugs is often the most useful therapeutic approach for the treatment of solid tumors. The use of injectable polymeric systems that maximize drug concentration in the proximal area of the tumor represents an extremely advantageous therapeutic strategy. Here, the development of an injectable in situ forming hydrogel was accomplished by exploiting the azo-type Michael reaction between an amine derivative of hyaluronic and vinylsulfone functionalized -cyclodextrins complexing doxorubicin. This injectable system can be easily prepared and administered with timelines compatible with normal operating room procedures, as demonstrated by rheological tests. In vitro…

medicine.medical_treatmentPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAnimal modelIn vivoNeoplasmsHyaluronic acidmedicineAnimalsDoxorubicinHyaluronic Acidchemistry.chemical_classificationCyclodextrinsChemotherapyCyclodextrinChemistryHydrogels021001 nanoscience & nanotechnologyIn vitroDrug concentrationDoxorubicinLocalized chemotherapy hyaluronic acid cyclodextrins in situ forming hydrogel DoxorubicinSettore CHIM/09 - Farmaceutico Tecnologico Applicativo0210 nano-technologyBiomedical engineeringmedicine.drug
researchProduct

Delivery of siHIF‐1α to Reconstruct Tumor Normoxic Microenvironment for Effective Chemotherapeutic and Photodynamic Anticancer Treatments

2021

The tumor hypoxic microenvironment not only induces genetic and epigenetic changes in tumor cells, immature vessels formation for oxygen demand, but also compromises the efficiency of therapeutic interventions. On the other hand, conventional therapeutic approaches which kill tumor cells or destroy tumor blood vessels to block nutrition and oxygen supply usually facilitate even harsher microenvironment. Thus, simultaneously relieving the strained response of tumor cells and blood vessels represents a promising strategy to reverse the adverse tumor hypoxic microenvironment. In the present study, an integrated amphiphilic system (RSCD) is designed based on Angiotensin II receptor blocker cand…

medicine.medical_treatmentPhotodynamic therapy02 engineering and technology010402 general chemistry01 natural sciencesBiomaterialsNeovascularizationchemistry.chemical_compoundIn vivoCell Line TumorTumor MicroenvironmentmedicineHumansGeneral Materials ScienceRNA Small InterferingHypoxiaChemotherapyTumor microenvironmentGeneral ChemistryHypoxia-Inducible Factor 1 alpha Subunit021001 nanoscience & nanotechnologyCell HypoxiaIn vitro0104 chemical sciencesOxygenchemistryDrug deliveryCancer researchmedicine.symptomGrowth inhibition0210 nano-technologyBiotechnologySmall
researchProduct